The antiphospholipid syndrome: Diagnosis, pathogenesis, laboratory testing, and management

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 4, 2012, Pages 299-303

  Favaloro, Emmanuel J ^a,b   Wong, Richard C W ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR RISK; CELL PROLIFERATION; HUMAN; LABORATORY TEST; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULARIZATION; VEIN THROMBOSIS;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; HUMANS;

EID: 84861329135     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1313565     Document Type: Review

References (38)

1. Asherson RA. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost: 2008; 34 3 227 235
2. Harris EN, Pierangeli SS. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name? Semin Thromb Hemost: 2008; 34 3 219 226
3. Favaloro EJ, Wong RCW. The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours? Autoimmunity Highlights: 2010; 1 5 14
4. Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med: 2011; 49 3 447 461
5. Miyakis S, Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 2 295 306
6. Pengo V, Tripodi A, Reber G., et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost: 2009; 7 10 1737 1740
7. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood: 2003; 101 5 1827 1832 (Pubitemid 36237580)
8. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood: 2003; 102 8 2717 2723 (Pubitemid 37248837)
9. Greco TP, Amos MD, Conti-Kelly AM, Naranjo JD, Ijdo JW. Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus: 2000; 9 1 33 41 (Pubitemid 30265116)
10. Lakos G, Kiss E, Regczy N., et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol: 1999; 117 3 574 579 (Pubitemid 29398308)
11. Yamada H, Tsutsumi A, Ichikawa K, Kato EH, Koike T, Fujimoto S. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum: 1999; 42 12 2727 2728 (Pubitemid 30327198)
12. Kumar S, Papalardo E, Sunkureddi P, Najam S, Gonzlez EB, Pierangeli SS. Isolated elevation of IgA anti-beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus: 2009; 18 11 1011 1014
13. Favaloro EJ, Wong RC. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost: 2008; 34 4 389 410
14. Favaloro EJ, Wong RCW. Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey. Pathology: 2009; 41 7 666 675
15. Mehdi AA, Salti I, Uthman I. Antiphospholipid syndrome: endocrinologic manifestations and organ involvement. Semin Thromb Hemost: 2011; 37 1 49 57
16. Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost: 2011; 37 2 141 145
17. Kenet G, Aronis S, Berkun Y., et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost: 2011; 37 7 802 809
18. Wong RC, Favaloro EJ. Antiphospholipid antibodies and the antiphospholipid syndrome. I: pathogenesis, clinical features, diagnosis, and management. Preface. Semin Thromb Hemost: 2008; 34 3 213 218
19. Wong RC, Favaloro EJ. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost: 2008; 34 3 295 304
20. Favaloro EJ, Wong RC. Antiphospholipid antibodies and the antiphospholipid syndrome II: limitations, standardization, and clinical utility of laboratory testing. Semin Thromb Hemost: 2008; 34 4 309 312
21. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost: 2012; 38 4 305 321
22. Pierangeli SS, Chen PP, Raschi E., et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost: 2008; 34 3 236 250
23. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. Semin Thromb Hemost: 2011; 37 5 431 439
24. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost: 2012; 38 4 322 327
25. Gillis D, Wong RCW. Rarer clinical associations of antiphospholipid antibodies. Semin Thromb Hemost: 2012; 38 4 328 332
26. Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the "CAPS Registryo" Semin Thromb Hemost: 2012; 38 4 333 338
27. Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost: 2008; 34 3 290 294
28. Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost: 2012; 38 4 339 347
29. Galli M. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin Thromb Hemost: 2008; 34 4 329 334
30. Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost: 2012; 38 4 348 352
31. Lakos G. Interference in antiphospholipid antibody assays. Semin Thromb Hemost: 2012; 38 4 353 359
32. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin Thromb Hemost: 2012; 38 4 360 374
33. Kershaw G, Suresh S, Orellana D, Nguy Y-M. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost: 2012; 38 4 375 384
34. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost: 1995; 74 4 1185 1190
35. Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost: 2012; 38 4 385 389
36. 2- glycoprotein I antibodies. Semin Thromb Hemost: 2012; 38 4 390 403
37. Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: part IIlupus anticoagulant. Semin Thromb Hemost: 2012; 38 4 404 411
38. de Groot PG, Urbanus RT. The future of antiphospholipid antibody testing. Semin Thromb Hemost: 2012; 38 4 412 420